Page last updated: 2024-08-07 15:39:07
Integrin beta-3
An integrin beta-3 that is encoded in the genome of human. [PRO:DNx]
Synonyms
Platelet membrane glycoprotein IIIa;
GPIIIa
Research
Bioassay Publications (101)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 34 (33.66) | 18.2507 |
| 2000's | 30 (29.70) | 29.6817 |
| 2010's | 31 (30.69) | 24.3611 |
| 2020's | 6 (5.94) | 2.80 |
Compounds (617)
Drugs with Potency Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| 1,2,4-trichlorobenzene | Homo sapiens (human) | Potency | 0.0158 | 1 | 0 |
| benzene | Homo sapiens (human) | Potency | 0.0040 | 1 | 0 |
| chlordecone | Homo sapiens (human) | Potency | 0.2512 | 1 | 0 |
| gallic acid | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| guaiacol | Homo sapiens (human) | Potency | 0.0126 | 1 | 0 |
| lactic acid | Homo sapiens (human) | Potency | 0.0251 | 1 | 0 |
| 1,10-phenanthroline | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 2,4-dinitrophenol | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| 3,4-dichloroisocoumarin | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 4-(2-aminoethyl)benzenesulfonylfluoride | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| 4-phenyl-3-furoxancarbonitrile | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 5-(n,n-hexamethylene)amiloride | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 5-(nonyloxy)tryptamine | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 7,8-dihydroxyflavone | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| tyrphostin 25 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| albendazole | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| amiodarone | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| amsacrine | Homo sapiens (human) | Potency | 1.0000 | 1 | 0 |
| anisindione | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| propiolactone | Homo sapiens (human) | Potency | 0.2512 | 1 | 0 |
| broxyquinoline | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| candesartan cilexetil | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| cantharidin | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| chelerythrine | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| chloroxine | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| chlorpromazine | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| clioquinol | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| clofoctol | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| clotrimazole | Homo sapiens (human) | Potency | 15.9775 | 1 | 0 |
| dequalinium | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| r 59022 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| diazinon | Homo sapiens (human) | Potency | 0.0050 | 1 | 0 |
| diphenyleneiodonium | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| disulfiram | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 2,3-dimethoxy-1,4-naphthoquinone | Homo sapiens (human) | Potency | 6.3096 | 1 | 0 |
| ellipticine | Homo sapiens (human) | Potency | 11.2947 | 1 | 0 |
| embelin | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| emodin | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| s-ethyl n-(4-(trifluoromethyl)phenyl)isothiourea | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| carbonyl cyanide p-trifluoromethoxyphenylhydrazone | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| fluphenazine | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| fluspirilene | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| vanoxerine | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| gbr 12935 | Homo sapiens (human) | Potency | 6.3096 | 1 | 0 |
| gossypol | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| hexylresorcinol | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| hydralazine | Homo sapiens (human) | Potency | 3.2465 | 1 | 0 |
| indirubin-3'-monoxime | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| indoprofen | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| iodoacetamide | Homo sapiens (human) | Potency | 6.3096 | 1 | 0 |
| iodoquinol | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| 1-(2-naphthalenyl)-2-propen-1-one | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| juglone | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| nsc 664704 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| beta-lapachone | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| leflunomide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| loratadine | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| vitamin k 3 | Homo sapiens (human) | Potency | 17.5594 | 1 | 0 |
| methoctramine | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| doxorubicin hydrochloride | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| methyl parathion | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| mitoxantrone | Homo sapiens (human) | Potency | 6.4776 | 1 | 0 |
| fg 7142 | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| deoxyepinephrine | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| etoposide phosphate | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| nabumetone | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| nialamide | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| niclosamide | Homo sapiens (human) | Potency | 3.4173 | 1 | 0 |
| nifedipine | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| nortriptyline | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| patulin | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| pd 98059 | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| perphenazine | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| phenindione | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| phenolphthalein | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| pifithrin | Homo sapiens (human) | Potency | 1.9953 | 1 | 0 |
| pomiferin | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| prazosin | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| prochlorperazine | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| propachlor | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| pyrimethamine | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 1,2,5,8-tetrahydroxy anthraquinone | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| raloxifene | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| riluzole | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| ritanserin | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| aurin | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| sanguinarine | Homo sapiens (human) | Potency | 4.4108 | 1 | 0 |
| sb 206553 | Homo sapiens (human) | Potency | 11.2947 | 1 | 0 |
| silymarin | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| spiperone | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| 2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| thiabendazole | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| ici 136,753 | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| triacetin | Homo sapiens (human) | Potency | 0.0398 | 1 | 0 |
| triamterene | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| trifluoperazine | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| trifluperidol | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| triflupromazine | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| tyrphostin a9 | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 6,18,30-trimethyl-3,9,12,15,21,24,27,33,36-nona(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone | Homo sapiens (human) | Potency | 0.1995 | 1 | 0 |
| 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| zm 336372 | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2,5-dichlorobenzoic acid | Homo sapiens (human) | Potency | 0.0501 | 1 | 0 |
| azauridine | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| mechlorethamine hydrochloride | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| cantharidin | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| cetrimonium bromide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| apomorphine | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| quinacrine monohydrochloride | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| trichloroacetic acid | Homo sapiens (human) | Potency | 0.0063 | 1 | 0 |
| isoprene | Homo sapiens (human) | Potency | 0.0050 | 1 | 0 |
| quinophthalone | Homo sapiens (human) | Potency | 0.3981 | 1 | 0 |
| salicylanilide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 1-naphthylphenylamine | Homo sapiens (human) | Potency | 0.0032 | 1 | 0 |
| benzidine | Homo sapiens (human) | Potency | 0.0079 | 1 | 0 |
| carveol | Homo sapiens (human) | Potency | 0.0079 | 1 | 0 |
| terephthalic acid | Homo sapiens (human) | Potency | 0.0050 | 1 | 0 |
| ethylbenzene | Homo sapiens (human) | Potency | 0.0063 | 1 | 0 |
| 1,3-diphenylurea | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 2,4-dimethylphenol | Homo sapiens (human) | Potency | 0.0501 | 1 | 0 |
| diethylamine | Homo sapiens (human) | Potency | 0.0079 | 1 | 0 |
| tetraethylenepentamine | Homo sapiens (human) | Potency | 0.0079 | 1 | 0 |
| chloranil | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| 3-nitrobenzoic acid | Homo sapiens (human) | Potency | 0.3162 | 1 | 0 |
| suramin sodium | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| di-n-pentyl phthalate | Homo sapiens (human) | Potency | 0.0079 | 1 | 0 |
| estragole | Homo sapiens (human) | Potency | 0.6310 | 1 | 0 |
| 2-chloroadenosine | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| benzo(k)fluoranthene | Homo sapiens (human) | Potency | 0.0063 | 1 | 0 |
| hydralazine hydrochloride | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| azacitidine | Homo sapiens (human) | Potency | 3.1623 | 1 | 0 |
| plumbagin | Homo sapiens (human) | Potency | 5.1454 | 1 | 0 |
| hematoxylin | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| dequalinium chloride | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| flavone | Homo sapiens (human) | Potency | 0.0050 | 1 | 0 |
| 2-methylfuran | Homo sapiens (human) | Potency | 0.0032 | 1 | 0 |
| gentian violet | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| eriodictyol | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 3-hydroxyflavone | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 6-aminoquinoline | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2,3-dichloro-1-propanol | Homo sapiens (human) | Potency | 0.0126 | 1 | 0 |
| 3,5-dichloroaniline | Homo sapiens (human) | Potency | 0.0100 | 1 | 0 |
| 3-methoxycatechol | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| ethidium bromide | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| tetrachloroisophthalonitrile | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| pimozide | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| fluometuron | Homo sapiens (human) | Potency | 0.0100 | 1 | 0 |
| 4-(octyloxy)benzoic acid | Homo sapiens (human) | Potency | 0.0020 | 1 | 0 |
| cladribine | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| hyaluronoglucosaminidase | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| camptothecin | Homo sapiens (human) | Potency | 0.0251 | 1 | 0 |
| diacerein | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| clemastine | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| metergoline | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| daunorubicin | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| thymolphthalein | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| 3,3',5,5'-tetramethylbenzidine | Homo sapiens (human) | Potency | 0.0040 | 1 | 0 |
| mitoxantrone hydrochloride | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| raloxifene hydrochloride | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| salmeterol xinafoate | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| niguldipine | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| mibefradil | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| aptiganel | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| paroxetine hydrochloride | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| sertraline hydrochloride | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| xanthyletine | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| sulconazole, mononitrate, (+-)-isomer | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| rutecarpine | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| toxoflavin | Homo sapiens (human) | Potency | 0.7943 | 1 | 0 |
| 2,6-dimethoxy-1,4-benzoquinone | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| nebularine | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| mianserin hydrochloride | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| miconazole nitrate | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 2,2',2''-terpyridine | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| masoprocol | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| hesperetin | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 2,5-di-tert-butyl-4-hydroxyanisole | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| atovaquone | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2,3-bis(benzoyloxy)tartaric acid | Homo sapiens (human) | Potency | 0.0079 | 1 | 0 |
| 4'-methoxyflavone | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| fentanyl isothiocyanate | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| mephentermine | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| prochlorperazine edisylate salt | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| n(6)-benzyladenosine | Homo sapiens (human) | Potency | 6.3096 | 1 | 0 |
| coumarin 7 | Homo sapiens (human) | Potency | 0.3162 | 1 | 0 |
| 5-Methoxyflavone | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| efuamide | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| osajin | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| zpck | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| 4-methoxydalbergione | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| alexidine dihydrchloride | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| tuamine sulfate | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| gr 127935 | Homo sapiens (human) | Potency | 25.7877 | 1 | 0 |
| 3',4'-dichlorobenzamil | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| eseroline | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 3-phenyl-1H-pyrazole-5-carboxylic acid | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| a 68930 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| indatraline | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| sb 200646 | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| methotrexate | Homo sapiens (human) | Potency | 0.1000 | 1 | 0 |
| 2-(3,4-dichlorophenyl)-n-methyl-n-(1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl)acetamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| n-(6-methoxy-8-quinolyl)-4-toluenesulfonamide | Homo sapiens (human) | Potency | 4.4668 | 1 | 0 |
| l 733060 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| cd 437 | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| n-phthaloylglutamic acid | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| tanshinone ii a | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| sb 216763 | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| sch 58261 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| chrysene-1,4-dione | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 4',6-dihydroxyflavone | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 1H-indol-3-yl-(4-methoxyphenyl)methanone | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| lilial | Homo sapiens (human) | Potency | 0.0100 | 1 | 0 |
| nsc 95397 | Homo sapiens (human) | Potency | 0.6310 | 1 | 0 |
| 3,6-bis(2-pyridyl)-1,2,4,5-tetrazine | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| nsc 663284 | Homo sapiens (human) | Potency | 3.1623 | 1 | 0 |
| nsc668394 | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| nsc681152 | Homo sapiens (human) | Potency | 6.3096 | 1 | 0 |
| mequindox | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| tosylphenylalanyl chloromethyl ketone | Homo sapiens (human) | Potency | 6.3096 | 1 | 0 |
| N-(3-Benzooxazol-2-yl-4-hydroxy-phenyl)-2-p-tolyloxyacetamide | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| sb 228357 | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| maleic acid | Homo sapiens (human) | Potency | 0.0079 | 1 | 0 |
| resveratrol | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| diethylstilbestrol | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 6-bromoindirubin-3'-oxime | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| purvalanol a | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione | Homo sapiens (human) | Potency | 1.1220 | 1 | 0 |
| 4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| 2-(2-phenoxyethylsulfonyl)-1H-benzimidazole | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 1,3-dichloro-7-methyl-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile | Homo sapiens (human) | Potency | 14.1254 | 1 | 0 |
| piplartine | Homo sapiens (human) | Potency | 3.1623 | 1 | 0 |
| 7-methoxyisoflavone | Homo sapiens (human) | Potency | 2.5119 | 1 | 0 |
| retinaldehyde | Homo sapiens (human) | Potency | 0.0126 | 1 | 0 |
| gw9662 | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| N-cyclopropyl-N-[2-[(4-methoxyphenyl)methylamino]-2-oxo-1-thiophen-2-ylethyl]-4-thiadiazolecarboxamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-(3H-benzimidazol-5-yl)-2-furancarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 3-chloro-1-cyclohexyl-4-(4-methyl-1-piperazinyl)pyrrole-2,5-dione | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-[3-[[2-furanyl(oxo)methyl]amino]phenyl]-1-isoquinolinecarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 3-amino-5-methoxy-2-benzofurancarboxylic acid methyl ester | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| N,N-dimethyl-6-phenyl-3-pyridazinamine | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(3-ethoxyphenyl)-1-(4-methoxyphenyl)sulfonyl-3-piperidinecarboxamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-(1,3-benzothiazol-2-yl)-N-methylbenzamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 6-methyl-3-[[[1-(phenylmethyl)-5-tetrazolyl]methyl-(thiophen-2-ylmethyl)amino]methyl]-1H-quinolin-2-one | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| N-cyclohexyl-N,4-dimethyl-5-thieno[3,2-b]pyrrolecarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| N-[2-(3-acetamidophenyl)-3H-benzimidazol-5-yl]acetamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 5-[3-(dimethylamino)phenyl]-N-methyl-1,3,4-thiadiazol-2-amine | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| N-[4-[oxo-(2-pyridinylamino)methyl]phenyl]-2-furancarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 1-[(1-tert-butyl-5-tetrazolyl)-thiophen-2-ylmethyl]-3,4-dihydro-2H-quinoline | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-[(3-ethyl-2-quinolinyl)thio]-N-(5-methyl-3-isoxazolyl)acetamide | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| N-(1,3-benzodioxol-5-yl)-3-[(2-methyl-1-oxopropyl)amino]benzamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| N-(3-dibenzofuranyl)-4-morpholinecarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-[2-methoxy-4-[(2-methyl-1-oxopropyl)amino]phenyl]-2-furancarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 3-(3-chlorophenyl)-1-(3-hydroxypropyl)-1-[(8-methyl-2-oxo-1H-quinolin-3-yl)methyl]urea | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 3-[3,4-dihydro-1H-isoquinolin-2-yl-[1-(2-methylbutan-2-yl)-5-tetrazolyl]methyl]-7-methoxy-1H-quinolin-2-one | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| 2-[[5-(6-methyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(5-methyl-3-isoxazolyl)acetamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 2-(ethylthio)-5-(4-methoxyphenyl)-1,3,4-oxadiazole | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| 3-[(2-fluorophenyl)methyl]-5-propyl-N-(pyridin-4-ylmethyl)-7-triazolo[4,5-d]pyrimidinamine | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 2-fluoro-N-[2-(4-fluorophenyl)-1,3-benzoxazol-5-yl]benzamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-[[2-(4-methoxyphenyl)-5-methyl-7-pyrazolo[1,5-a]pyrimidinyl]amino]ethanol | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-methoxyacetamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| [4-[5-tert-butyl-3-[(2-chlorophenyl)methyl]-7-triazolo[4,5-d]pyrimidinyl]-1-piperazinyl]-(2-furanyl)methanone | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 3-chloro-4-[4-(4-fluorophenyl)sulfonyl-1-piperazinyl]-N,N-dimethylbenzenesulfonamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| (6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]methanone | Homo sapiens (human) | Potency | 6.3096 | 1 | 0 |
| [4-[2-(3-chlorophenyl)-5-methyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]-(2-furanyl)methanone | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-(2-pyrimidinyl)-3-piperidinecarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 4-methyl-N-(2-methyl-5-tetrazolyl)benzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-[2-[2-[2-(4-methoxyanilino)-2-oxoethyl]-5-tetrazolyl]phenyl]-2-furancarboxamide | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 8-(butan-2-ylthio)-7-[(4-chlorophenyl)methyl]-3-methylpurine-2,6-dione | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 9-oxo-N-(3-pyridinylmethyl)-3,6-dihydro-2H-[1,4]dioxino[2,3-g]quinoline-8-carboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-[[6-(3,4-dimethoxyphenyl)-3-pyridazinyl]thio]-1-(4-morpholinyl)ethanone | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| N-[3-chloro-4-(4-morpholinyl)phenyl]-2-furancarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-[[1-(4-methylphenyl)-4-pyrazolo[3,4-d]pyrimidinyl]thio]acetic acid ethyl ester | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-[2-(4-chloro-N-[2-(cyclohexylamino)-2-oxoethyl]anilino)-2-oxoethyl]-2-furancarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 2-[[5-(4-chlorophenyl)-1-(2-methoxyethyl)-2-imidazolyl]thio]-N-(thiophen-2-ylmethyl)acetamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 5-bromo-3-[[2-(4-cyclohexyl-1-piperazinyl)-1-oxoethyl]amino]-1H-indole-2-carboxylic acid methyl ester | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| 2-[[2-(3-methoxyphenoxy)-1-oxoethyl]amino]benzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 4-(3-amino-5-bromo-2-benzofuranyl)-4-oxobutanoic acid methyl ester | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-(2-oxo-3H-1,4-benzoxazin-4-yl)acetic acid [2-(3-bromo-4-methoxyphenyl)-2-oxoethyl] ester | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 5,6-dimethoxy-3-[[(3-methoxyphenyl)-oxomethyl]amino]-1H-indole-2-carboxylic acid methyl ester | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 4-(2-furanyl)-3-methyl-5-(4-methylphenyl)-2,4-dihydropyrrolo[3,4-c]pyrazol-6-one | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 3-(3-benzoyl-6-chloro-4,5-dihydroxy-7-benzofuranyl)pentane-2,4-dione | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 3-phenyl-1H-cinnolin-4-one | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-methylpropanamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-ethylpropanamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 1-[2-[cyano-(4,6-dimethyl-2-pyrimidinyl)amino]-1-oxoethyl]-4-piperidinecarboxamide | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| N-(3,4-dihydro-1H-[1,4]thiazino[4,3-a]benzimidazol-8-yl)pentanamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 4-[[1-oxo-2-(3-oxo-2-thiomorpholinyl)ethyl]amino]benzoic acid ethyl ester | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 5-(3-methoxyphenyl)-N-(2-oxolanylmethyl)-7-(trifluoromethyl)-3-pyrazolo[1,5-a]pyrimidinecarboxamide | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| dienestrol | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| mercaptopurine | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 4-methoxy-N-(5-methyl-3-isoxazolyl)benzamide | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| 2,4-difluoro-N-[[(5-methyl-1H-pyrazol-3-yl)amino]-oxomethyl]benzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 1-(4-amino-2-methyl-3-quinolinyl)ethanone | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-[4-(diethylamino)phenyl]-2-furancarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 7,8,3'-trihydroxyflavone | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| phenylthiourea | Homo sapiens (human) | Potency | 0.0398 | 1 | 0 |
| 4-methyl-N-[4-(4-morpholinyl)phenyl]benzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| sch-202676 | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 6-methoxy-2-(4-methoxyphenyl)-1-benzopyran-4-one | Homo sapiens (human) | Potency | 0.7943 | 1 | 0 |
| 6-methylflavone | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-methoxy-N-(2-pyridinyl)benzamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,5-dimethyl-3-furamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 1-(1,3-benzodioxol-5-yl)-4-hydroxy-3-pyrazolecarboxylic acid ethyl ester | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| ceefourin 1 | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| N-tert-butyl-1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(4-oxo-3-quinazolinyl)acetamide | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| N-(5-methyl-3-isoxazolyl)-1,3-benzodioxole-5-carboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| vu0038882 | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-methoxybenzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(4-methoxyphenyl)-2-benzofurancarboxamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 5-amino-1-(2-pyridinyl)-4-pyrazolecarboxylic acid ethyl ester | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 1-cyclohexyl-3-(2-phenylethyl)urea | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| nsc185058 | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 2-[(2-fluorophenyl)methylthio]-5-(4-methylphenyl)-1,3,4-oxadiazole | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-[3-(6-imidazo[2,1-b]thiazolyl)phenyl]butanamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| N-(3,4-dimethoxyphenyl)-4-methoxybenzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| cid755673 | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| 2-(4-chlorophenyl)-5-(4-fluorophenyl)-1,3,4-oxadiazole | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| N-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-furancarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 1-(4,5-dihydrothiazol-2-yl)-3-phenylurea | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 4-methyl-N-[1-[2-(1-pyrrolidinyl)ethyl]-2-benzimidazolyl]benzamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 2-(phenylmethylthio)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-(2-chloro-6-fluorophenyl)-1-(2,4-dihydroxyphenyl)ethanone | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 5-bromo-N-(4-propan-2-ylphenyl)-2-furancarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 6-(1,3-benzoxazol-2-yl)-1,3-benzothiazol-2-amine | Homo sapiens (human) | Potency | 35.4813 | 1 | 0 |
| 2-methyl-N-(2-naphthalenyl)-3-furancarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 2-amino-5-[diethylamino(oxo)methyl]-4-methyl-3-thiophenecarboxylic acid propan-2-yl ester | Homo sapiens (human) | Potency | 0.0100 | 1 | 0 |
| N-(1,3-benzodioxol-5-yl)-5-methyl-2-furancarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 1-cyclohexyl-3-(2,3-dihydro-1,4-benzodioxin-6-yl)urea | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| N-(1-acetyl-2,3-dihydroindol-5-yl)-4-methylbenzamide | Homo sapiens (human) | Potency | 6.3096 | 1 | 0 |
| 2-[(2-chlorophenoxy)methyl]benzoic acid | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 5-(4-propan-2-ylphenyl)-2H-tetrazole | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(1,3-benzodioxol-5-yl)-4-(4-morpholinylmethyl)benzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-[3-[methyl(methylsulfonyl)amino]phenyl]-2-phenoxyacetamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(4-ethoxyphenyl)-1,2,5-thiadiazole-3-carboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 3-(2-methoxy-6-methyl-3-pyridinyl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(2-methyl-5-tetrazolyl)-2-naphthalenecarboxamide | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| curcumin | Homo sapiens (human) | Potency | 39.8107 | 1 | 0 |
| 4-(2-naphthalenyloxymethyl)-2-thiazolamine | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-(2-pyridinyl)-2-[[5-(3-pyridinyl)-1,3,4-oxadiazol-2-yl]thio]acetamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 2,3,5,6-tetramethyl-N-(2-methyl-1,3-benzothiazol-5-yl)benzenesulfonamide | Homo sapiens (human) | Potency | 14.1254 | 1 | 0 |
| 3-(n-benzylsulfamoyl)-4-bromo-n-(4-bromophenyl)benzamide | Homo sapiens (human) | Potency | 11.2202 | 1 | 0 |
| 4-[[[3-(4-morpholinylsulfonyl)phenyl]-oxomethyl]amino]benzoic acid ethyl ester | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 5-(3,4-dimethoxyphenyl)-2-phenyl-4-thieno[2,3-d][1,3]oxazinone | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-[2-(3-pyridinyl)-3H-benzimidazol-5-yl]-2-furancarboxamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 5-(4-methylphenyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| N-(4-cyano-2-methyl-3-pyrazolyl)-5-(4-methylphenyl)-3-isoxazolecarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| [4-(diphenylmethyl)-1-piperazinyl]-[5-thiophen-2-yl-7-(trifluoromethyl)-3-pyrazolo[1,5-a]pyrimidinyl]methanone | Homo sapiens (human) | Potency | 4.4668 | 1 | 0 |
| 2-[(4-bromophenoxy)methyl]-5-[2-(3,4-dimethoxyphenyl)ethylamino]-4-oxazolecarbonitrile | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| N-(1,2,4-triazol-4-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-2-carboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide | Homo sapiens (human) | Potency | 11.2202 | 1 | 0 |
| N-[5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl]-5-methyl-3-isoxazolecarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 5-[[[4-(4-fluorophenyl)-5-(phenylmethyl)-1,2,4-triazol-3-yl]thio]methyl]-3-thiophen-2-yl-1,2,4-oxadiazole | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-(4-chlorophenyl)-N-[[2-(4-morpholinyl)anilino]-sulfanylidenemethyl]acetamide | Homo sapiens (human) | Potency | 2.5119 | 1 | 0 |
| N-[6-(diethylsulfamoyl)-1,3-benzothiazol-2-yl]-2-thiophenecarboxamide | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 2,4-dichloro-5-(diethylsulfamoyl)-N-(1,3,4-thiadiazol-2-yl)benzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 4-[[diethylamino(oxo)methyl]amino]benzoic acid ethyl ester | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(2,3-dihydro-1H-inden-5-yl)-5-methyl-2-pyrazinecarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-amino-6-ethyl-3-(3-isoxazolyl)-7-methoxy-1-benzopyran-4-one | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| cis-resveratrol | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| fluoxetine | Homo sapiens (human) | Potency | 22.9651 | 1 | 0 |
| 4-amino-2-[[4-amino-6-(4-fluoroanilino)-1,3,5-triazin-2-yl]methylthio]-5-pyrimidinecarboxylic acid ethyl ester | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-chloro-N-heptyl-N-(3-methylphenyl)acetamide | Homo sapiens (human) | Potency | 35.4813 | 1 | 0 |
| 1-[(3,4-dichlorophenyl)methyl]indole-2,3-dione | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 2-[[2-[(1-cyclohexyl-5-tetrazolyl)thio]-1-oxoethyl]amino]benzoic acid methyl ester | Homo sapiens (human) | Potency | 6.3096 | 1 | 0 |
| N-[4-[[2-[1-(2-methoxyethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl]thio]phenyl]acetamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 2-ethoxy-3-pyridinecarboxylic acid [2-[1-(2-furanylmethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(3,4-dihydro-2H-pyrrol-5-yl)-5-(2-furanyl)-1,3,4-oxadiazol-2-amine | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| 3-[[[4-(phenylmethyl)-5-thiophen-2-yl-1,2,4-triazol-3-yl]thio]methyl]-1,2,3-benzotriazin-4-one | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 2-(2,4-dioxo-1H-pyrimidin-6-yl)-N-[2-(4-morpholinyl)ethyl]acetamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-[[3-(4-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]acetic acid ethyl ester | Homo sapiens (human) | Potency | 1.2589 | 1 | 0 |
| 2-[[oxo-(2,3,4,5,6-pentafluorophenyl)methyl]amino]benzoic acid ethyl ester | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-[(3-ethoxy-2-prop-2-enoxyphenyl)methyl]-2-thiazolamine | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-[[1-oxo-2-(1H-1,2,4-triazol-5-ylthio)ethyl]amino]-4-thiophen-2-yl-3-thiophenecarboxylic acid ethyl ester | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| N-[3-[[2-(2,6-dimethylphenoxy)-1-oxoethyl]amino]phenyl]-2-furancarboxamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-dibenzofuransulfonamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-(3-acetylphenyl)-5,7-dimethyl-2-pyrazolo[1,5-a]pyrimidinecarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-([1,2,4]triazolo[4,3-a]pyridin-3-ylthio)ethanone | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-((3-(2,3-dichlorophenoxy)propyl)amino)ethanol | Homo sapiens (human) | Potency | 1.2589 | 1 | 0 |
| N-[2,2-dichloro-1-(3-fluoro-4-methylphenyl)ethenyl]-4-morpholinecarboxamide | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 5,6,7,8-tetrafluoro-2-(2,3,4,5,6-pentafluorophenyl)-4h-1-benzopyran-4-one | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(3,5-dimethyl-1-pyrazolyl)benzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| [2-[(2-bromophenyl)methoxy]phenyl]-[4-(2-pyrimidinyl)-1-piperazinyl]methanone | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 4-(4-methyl-1-piperidinyl)-5-phenyl-2-(3-pyridinyl)thieno[2,3-d]pyrimidine | Homo sapiens (human) | Potency | 0.0224 | 1 | 0 |
| 2-(2,3-dihydro-1H-inden-5-yloxy)-1-(2,3-dihydroindol-1-yl)ethanone | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 1-[2-(4-methoxyphenoxy)ethylthio]-[1,2,4]triazolo[3,4-b][1,3]benzothiazole | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| thioguanine anhydrous | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| digoxin | Homo sapiens (human) | Potency | 0.1995 | 1 | 0 |
| malachite green | Homo sapiens (human) | Potency | 0.7943 | 1 | 0 |
| tamoxifen citrate | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| tamoxifen | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| tetraoctylammonium bromide | Homo sapiens (human) | Potency | 0.7943 | 1 | 0 |
| methyl-thiohydantoin-tryptophan | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 4-ethyl-2-methoxy-3-phenyl-3,3a,9,9a-tetrahydropyrrolo[2,3-b]quinoxaline | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 1-ethoxy-3-(2-methoxy-4-prop-2-enylphenoxy)-2-propanol | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| alanyl-alanyl-alanyl-alanine, (d-ala-l-ala-l-ala-l-ala)-isomer | Homo sapiens (human) | Potency | 3.1623 | 1 | 0 |
| 1-(1-benzotriazolyl)-3-(10-phenothiazinyl)-2-propanol | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 2,2'-[3-(2-methoxyphenyl)-1,2-propanediyl]bis(1H-benzimidazole) | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 6-amino-4-[3-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-4-methoxyphenyl]-3-methyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 1-(4-methoxyphenyl)-N,N-dipropyl-4-pyrazolo[3,4-d]pyrimidinamine | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-[(9-tert-butyl-1,5-dicyano-2-oxo-3-azaspiro[5.5]undec-4-en-4-yl)thio]-N-cyclohexylacetamide | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| N-(3,4-dimethylphenyl)-2-(4-methylanilino)-6-oxo-4,5-dihydro-1H-pyrimidine-4-carboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(5-chloro-2-hydroxyphenyl)-2-ethoxybenzamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methoxy-4-propan-2-yloxybenzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-[[4-(4-fluorophenyl)-6-(trifluoromethyl)-2-pyrimidinyl]sulfonyl]acetic acid ethyl ester | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-(3-methyl-1,3-benzothiazol-2-ylidene)-2-pyrazinecarboxamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| N-(1,3-benzothiazol-2-yl)-2-oxolanecarboxamide | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| 2-[2-[2,5-dimethyl-1-(thiophen-2-ylmethyl)-3-pyrrolyl]-2-oxoethyl]isoindole-1,3-dione | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 2-[2-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-2-oxoethyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| l 783281 | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| zephiran | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 6-methyl-2-(phenylethynyl)pyridine | Homo sapiens (human) | Potency | 14.2191 | 1 | 0 |
| zuclomifene citrate | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| triptorelin | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| u-50488 | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| bp 897 | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| erysolin | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 7-(2-methoxyphenyl)-5-phenyl-1,7-dihydrotetrazolo[1,5-a]pyrimidine | Homo sapiens (human) | Potency | 35.4813 | 1 | 0 |
| N-(2-furanylmethyl)-6-(3-methoxyphenyl)-N-methyl-4-quinazolinamine | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| N-(1,3-benzodioxol-5-yl)-2-(5-methyl-2-furanyl)-3-imidazo[1,2-a]pyrimidinamine | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| 2-[[3-(4-methoxyphenyl)-1,2,4-thiadiazol-5-yl]thio]acetic acid ethyl ester | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| (7-methoxy-4,5-dihydrobenzo[g][1,2]benzoxazol-3-yl)-(4-morpholinyl)methanone | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-(2-methoxyphenyl)-1-oxo-N-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-4-isoquinolinecarboxamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| N-[2-(6,7-dimethyl-2-oxo-1H-quinolin-3-yl)ethyl]-1-propanesulfonamide | Homo sapiens (human) | Potency | 0.0079 | 1 | 0 |
| N-[4-[5-[(2-methylphenoxy)methyl]-1,2,4-oxadiazol-3-yl]phenyl]-2-furancarboxamide | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| 6-[4-(3-chlorophenyl)-1-piperazinyl]-3-cyclohexyl-1H-pyrimidine-2,4-dione | Homo sapiens (human) | Potency | 3.1623 | 1 | 0 |
| 1-(2-methoxyethyl)-2-[(4-methylphenoxy)methyl]benzimidazole | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 4-hydroxy-1-[1-oxo-2-[[1-oxo-2-(phenylmethoxycarbonylamino)ethyl]amino]propyl]-2-pyrrolidinecarboxylic acid (phenylmethyl) ester | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| 1,7,7-trimethyl-9-oxo-N-(2-oxolanylmethyl)-8H-furo[3,2-f][1]benzopyran-2-carboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 5-bromo-N-[2-(2-chlorophenyl)-1,3-benzoxazol-5-yl]-3-pyridinecarboxamide | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| 5-ethyl-N-[2-(2-phenyl-4-thiazolyl)ethyl]-2-thiophenesulfonamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-(2,4-dimethoxyanilino)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-quinolinecarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 2-[(5-bromo-2-thiophenyl)sulfonyl-methylamino]-N-(6-methyl-1,3-benzothiazol-2-yl)acetamide | Homo sapiens (human) | Potency | 0.6310 | 1 | 0 |
| N-(2-methoxyethyl)-5-(3-methoxyphenyl)-3-isoxazolecarboxamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-[4-[[4-(2-fluorophenyl)-1-piperazinyl]-oxomethyl]-1-oxo-2-isoquinolinyl]-2-pyrazinecarboxamide | Homo sapiens (human) | Potency | 0.0631 | 1 | 0 |
| 2-(1,3-benzodioxol-5-yl)-3-hydroxy-1,2-dihydroquinazolin-4-one | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-methyl-4-oxo-1-phthalazinyl)acetamide | Homo sapiens (human) | Potency | 0.2512 | 1 | 0 |
| N-[4-methyl-2-(4-methyl-1-piperazinyl)-6-quinolinyl]-1,3-benzodioxole-5-carboxamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| [4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-(7-methoxy-2-furo[2,3-b]quinolinyl)methanone | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 3,4-dihydro-2H-quinolin-1-yl-[5-(4-methoxyphenyl)-3-isoxazolyl]methanone | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 3-(4-methoxyphenyl)-3-(1-pyrrolyl)-N-(2-thiazolyl)propanamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-(4-ethoxyphenyl)-2-(hydroxymethyl)benzamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| [4-(2-pyrimidinyl)-1-piperazinyl]-[1-[4-(2-pyrimidinyl)-1-piperazinyl]-4-isoquinolinyl]methanone | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-2-[(1-ethyl-2-oxo-4-quinolinyl)oxy]acetamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-(7-methyl-4-oxo-3-furo[3,4]pyrrolo[3,5-c][1,2,4]triazinyl)acetic acid methyl ester | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| N,3-diphenyl-1-pyrrolidinecarboxamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| N-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 3-(4-methylphenyl)-N-phenyl-1-pyrrolidinecarboxamide | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| N-butan-2-yl-6-[(4-ethoxyphenyl)sulfamoyl]-4-oxo-1H-quinoline-3-carboxamide | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| 2-(2-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| N-[3-(cyclohexylthio)propyl]-1-[(4-methyl-5-thieno[3,2-b]pyrrolyl)-oxomethyl]-3-piperidinecarboxamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-[4-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-oxomethyl]phenyl]-2-oxolanecarboxamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 3-hydroxy-2-(2-hydroxy-3-methoxyphenyl)-1,2-dihydroquinazolin-4-one | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 8-(2-propoxyphenyl)-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]quinolin-6-one | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| sb-224289 | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| gw 7647 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| ro 41-0960 | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| l 663536 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| rs 17053 | Homo sapiens (human) | Potency | 39.8107 | 1 | 0 |
| ro 106-9920 | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 4-chloro-5-(2,3-dihydro-1,4-benzodioxin-3-yl)thieno[2,3-d]pyrimidine | Homo sapiens (human) | Potency | 22.3872 | 1 | 0 |
| 3,5-bis(4-methoxyphenyl)-1H-imidazole-2-thione | Homo sapiens (human) | Potency | 3.5481 | 1 | 0 |
| 5-[[2-[2-[[cyclohexyl(oxo)methyl]amino]-1-oxoethoxy]-1-oxoethyl]amino]-3-methylthiophene-2,4-dicarboxylic acid diethyl ester | Homo sapiens (human) | Potency | 0.7079 | 1 | 0 |
| 3-methoxy-N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]benzamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 1-(5-methyl-2-furanyl)-2-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)-1H-[1]benzopyrano[2,3-c]pyrrole-3,9-dione | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| sch 79797 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| am 630 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-[8-[(2,6-dimethyl-4-morpholinyl)methyl]-1,3-dimethyl-2,6-dioxo-7-purinyl]acetic acid ethyl ester | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-[[1-(2-phenoxyethyl)-2-benzimidazolyl]methyl]aniline | Homo sapiens (human) | Potency | 0.0089 | 1 | 0 |
| 2-[8-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-1,3-dimethyl-2,6-dioxo-7-purinyl]acetic acid methyl ester | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| cgp 7930 | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1h-pyrazole | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 1,3-dimethyl-8-(3-methyl-1-piperidinyl)-7-[2-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]ethyl]purine-2,6-dione | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| 1-[2-[(4-pentoxyphenyl)methylthio]ethyl]-3-phenylthiourea | Homo sapiens (human) | Potency | 1.0000 | 1 | 0 |
| ncgc00099374 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| sib 1757 | Homo sapiens (human) | Potency | 19.9526 | 1 | 0 |
| quercetin | Homo sapiens (human) | Potency | 2.5119 | 1 | 0 |
| biochanin a | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| formononetin | Homo sapiens (human) | Potency | 8.7169 | 1 | 0 |
| acacetin | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| apigenin | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| luteolin | Homo sapiens (human) | Potency | 8.8006 | 1 | 0 |
| kaempferol | Homo sapiens (human) | Potency | 5.9622 | 1 | 0 |
| genistein | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| baicalein | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| chrysin | Homo sapiens (human) | Potency | 28.3708 | 1 | 0 |
| 3,7,4'-trihydroxyflavone | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| fisetin | Homo sapiens (human) | Potency | 13.9668 | 1 | 0 |
| mangostin | Homo sapiens (human) | Potency | 20.8114 | 1 | 0 |
| daidzein | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| Pinosylvin methyl ether | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| chicoric acid | Homo sapiens (human) | Potency | 0.0063 | 1 | 0 |
| n-oleoyldopamine | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| tranilast | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| perhexiline maleate | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| fenretinide | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| ic 261 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| su 9516 | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid | Homo sapiens (human) | Potency | 39.8107 | 1 | 0 |
| N-(5-bromo-2-thiazolyl)-3-phenyl-2-(1-pyrrolyl)propanamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 4-[5-(4-methoxyphenyl)-3-isoxazolyl]-N-(2-pyridinylmethyl)butanamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 3-[[4-[6-(4-morpholinyl)-3-pyridazinyl]-1-piperazinyl]-oxomethyl]-1-benzopyran-2-one | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 3-(4-chlorophenyl)-1-methyl-N-[3-(1-pyrrolidinyl)propyl]-5-thieno[2,3-c]pyrazolecarboxamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 4-[3-(4-fluorophenyl)-2-methyl-7-oxo-1H-pyrazolo[1,5-a]pyrimidin-5-yl]-1-piperidinecarboxylic acid ethyl ester | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 1-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methyl]-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-3-piperidinecarboxamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-(3-acetylphenyl)-5-propan-2-yl-3-isoxazolecarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 2-(2-chlorophenyl)-9-(3-methylphenyl)-8-oxo-7H-purine-6-carboxamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 3-[3-[(5-ethyl-[1,2,4]triazino[5,6-b]indol-3-yl)thio]propyl]-1H-benzimidazol-2-one | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| olvanil | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| k 185 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| sr 59230a | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| isoginkgetin | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 5,7,2'-trihydroxyflavone | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| furazolidone | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| tyrphostin ag 555 | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| tyrphostin ag-494 | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 6,7-dihydroxyflavone | Homo sapiens (human) | Potency | 2.5119 | 1 | 0 |
| nitrofurazone | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| n'-((1e)-(4-(diethylamino)phenyl)methylene)-4-hydroxybenzohydrazide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| methylbenzethonium chloride | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| derrubone | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| gw-5074 | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| cinalukast | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| a 77636 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| b 43 | Homo sapiens (human) | Potency | 25.1189 | 1 | 0 |
| gw2974 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| l 162313 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| sb 222200 | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| suloctidil | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| am 404 | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| omdm-2 cpd | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| sb 334867-a | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| aminopurvalanol a | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| bvt.948 | Homo sapiens (human) | Potency | 1.2589 | 1 | 0 |
| Retusin 7-Methyl Ether | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| chlorhexidine | Homo sapiens (human) | Potency | 0.0079 | 1 | 0 |
| lassbio 294 | Homo sapiens (human) | Potency | 8.9125 | 1 | 0 |
| y 27632, dihydrochloride, (4(r)-trans)-isomer | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| [9-(benzenesulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]-(4-methylphenyl)methanone | Homo sapiens (human) | Potency | 17.7828 | 1 | 0 |
| 4-methylbenzoic acid [6-[[[5-[[cyclopropyl(oxo)methyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]-4-oxo-3-pyranyl] ester | Homo sapiens (human) | Potency | 0.0178 | 1 | 0 |
| 2-[[5-(2-methylanilino)-1,3,4-thiadiazol-2-yl]thio]-N-(2-nitrophenyl)acetamide | Homo sapiens (human) | Potency | 6.3096 | 1 | 0 |
| 2-(2-methoxyanilino)-8-[(3-methyl-1-piperidinyl)-oxomethyl]-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 2-[(7-chloro-1,2,3,4-tetrahydroacridin-9-yl)thio]-N-(3-methoxypropyl)acetamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| 5-chloro-2-[(4-methylphenyl)methylsulfonyl]-N-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)-4-pyrimidinecarboxamide | Homo sapiens (human) | Potency | 12.5893 | 1 | 0 |
| 5-chloro-2-[(3-methylphenyl)methylsulfonyl]-N-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)-4-pyrimidinecarboxamide | Homo sapiens (human) | Potency | 15.8489 | 1 | 0 |
| 4-(6-chloro-2-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)-4-oxo-N-(phenylmethyl)butanamide | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| N-[5-[ethyl(phenyl)sulfamoyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide | Homo sapiens (human) | Potency | 2.5119 | 1 | 0 |
| [3-methyl-4-(3-methylphenyl)-1-piperazinyl]-[1-(7,8,9,10-tetrahydro-6H-purino[9,8-a]azepin-4-yl)-4-piperidinyl]methanone | Homo sapiens (human) | Potency | 35.4813 | 1 | 0 |
| 3-[3,5-dimethyl-1-[6-(1-piperidinyl)-3-pyridazinyl]-4-pyrazolyl]-N-(3-fluorophenyl)propanamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 3-[3,5-dimethyl-1-[6-(1-piperidinyl)-3-pyridazinyl]-4-pyrazolyl]-N-(3-fluoro-4-methylphenyl)propanamide | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| 3,5-dimethoxy-N-[1-[oxo(thiophen-2-yl)methyl]-3,4-dihydro-2H-quinolin-6-yl]benzamide | Homo sapiens (human) | Potency | 5.0119 | 1 | 0 |
| phenylmercuric acetate | Homo sapiens (human) | Potency | 1.0000 | 1 | 0 |
| thimerosal | Homo sapiens (human) | Potency | 1.0000 | 1 | 0 |
| u 63557a | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| dicumarol | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
| robustic acid | Homo sapiens (human) | Potency | 7.9433 | 1 | 0 |
| 4-hydroxy-3-(1-piperidinylmethyl)-1-benzopyran-2-one | Homo sapiens (human) | Potency | 31.6228 | 1 | 0 |
| kf38789 | Homo sapiens (human) | Potency | 3.9811 | 1 | 0 |
| azaguanine | Homo sapiens (human) | Potency | 10.0000 | 1 | 0 |
Drugs with Inhibition Measurements
Drugs with Activation Measurements
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| tirofiban | Homo sapiens (human) | ED50 | 0.0010 | 1 | 1 |
| l 738167 | Homo sapiens (human) | ED50 | 0.0001 | 1 | 1 |
| l 734217 | Homo sapiens (human) | ED50 | 0.0050 | 1 | 1 |
| mk-0429 | Homo sapiens (human) | SPAV3 | 0.0001 | 1 | 1 |
Tuning the Biological Activity of RGD Peptides with Halotryptophans†.Journal of medicinal chemistry, , 01-14, Volume: 64, Issue:1, 2021
Novel cilengitide-based cyclic RGD peptides as αvβBioorganic & medicinal chemistry letters, , 04-15, Volume: 30, Issue:8, 2020
Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.Journal of medicinal chemistry, , 06-11, Volume: 63, Issue:11, 2020
Cyclization of RGD Peptides by Suzuki-Miyaura Cross-Coupling.Journal of medicinal chemistry, , 08-22, Volume: 62, Issue:16, 2019
Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation.European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
Synthesis, biological evaluation and molecular docking studies of 2-piperazin-1-yl-quinazolines as platelet aggregation inhibitors and ligands of integrin αIIbβ3.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 26, Issue:7, 2016
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.Journal of medicinal chemistry, , 11-10, Volume: 59, Issue:21, 2016
Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.Journal of medicinal chemistry, , Oct-08, Volume: 58, Issue:19, 2015
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.Journal of medicinal chemistry, , Jul-10, Volume: 57, Issue:13, 2014
Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ₃.Bioorganic & medicinal chemistry, , Aug-01, Volume: 21, Issue:15, 2013
Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.European journal of medicinal chemistry, , Volume: 64, 2013
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes α5β1 and αvβ6: conformational control through flanking amino acids.Journal of medicinal chemistry, , Feb-28, Volume: 56, Issue:4, 2013
Tailoring of integrin ligands: probing the charge capability of the metal ion-dependent adhesion site.Journal of medicinal chemistry, , Jan-26, Volume: 55, Issue:2, 2012
Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.European journal of medicinal chemistry, , Volume: 50, 2012
Molecular model of the alpha(IIb)beta(3) integrin.Journal of medicinal chemistry, , Dec-04, Volume: 46, Issue:25, 2003
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.Journal of medicinal chemistry, , Sep-21, Volume: 43, Issue:19, 2000
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors.Bioorganic & medicinal chemistry letters, , Sep-04, Volume: 10, Issue:17, 2000
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.Journal of medicinal chemistry, , Jul-01, Volume: 42, Issue:13, 1999
Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes.Journal of medicinal chemistry, , Jun-04, Volume: 41, Issue:12, 1998
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.Journal of medicinal chemistry, , Aug-05, Volume: 37, Issue:16, 1994
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.Journal of medicinal chemistry, , Nov-27, Volume: 35, Issue:24, 1992
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.Journal of medicinal chemistry, , Sep-21, Volume: 43, Issue:19, 2000
Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.Journal of medicinal chemistry, , Dec-06, Volume: 39, Issue:25, 1996
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.Journal of medicinal chemistry, , Jul-10, Volume: 57, Issue:13, 2014
Molecular model of the alpha(IIb)beta(3) integrin.Journal of medicinal chemistry, , Dec-04, Volume: 46, Issue:25, 2003
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.Bioorganic & medicinal chemistry letters, , Jan-07, Volume: 12, Issue:1, 2002
Determination of the binding specificity of an integral membrane protein by saturation transfer difference NMR: RGD peptide ligands binding to integrin alphaIIbbeta3.Journal of medicinal chemistry, , Sep-13, Volume: 44, Issue:19, 2001
Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp).European journal of medicinal chemistry, , Sep-18, Volume: 102, 2015
Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ₃.Bioorganic & medicinal chemistry, , Aug-01, Volume: 21, Issue:15, 2013
RGD mimetics containing phthalimidine fragment as novel ligands of fibrinogen receptor.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 21, Issue:19, 2011
Derivatives of tetrahydroisoquinoline: synthesis and initial evaluation of novel non-peptide antagonists of the alpha(IIb)beta(3)-integrin.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 20, Issue:15, 2010
Determination of the binding specificity of an integral membrane protein by saturation transfer difference NMR: RGD peptide ligands binding to integrin alphaIIbbeta3.Journal of medicinal chemistry, , Sep-13, Volume: 44, Issue:19, 2001
Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.Journal of medicinal chemistry, , Feb-12, Volume: 41, Issue:4, 1998
Design of a new class of orally active fibrinogen receptor antagonists.Journal of medicinal chemistry, , Jul-02, Volume: 41, Issue:14, 1998
Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation.Journal of medicinal chemistry, , Jan-06, Volume: 38, Issue:1, 1995
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.Journal of medicinal chemistry, , Nov-27, Volume: 35, Issue:24, 1992
alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers.Journal of medicinal chemistry, , Nov-26, Volume: 52, Issue:22, 2009
Cyclic RGD peptide analogues as antiplatelet antithrombotics.Journal of medicinal chemistry, , May-29, Volume: 35, Issue:11, 1992
Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.Journal of medicinal chemistry, , Jun-07, Volume: 44, Issue:12, 2001
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.Journal of medicinal chemistry, , Aug-12, Volume: 42, Issue:16, 1999
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors.Bioorganic & medicinal chemistry letters, , Sep-04, Volume: 10, Issue:17, 2000
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.Journal of medicinal chemistry, , Jun-06, Volume: 40, Issue:12, 1997
Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design.Journal of medicinal chemistry, , Oct-09, Volume: 46, Issue:21, 2003
Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.Journal of medicinal chemistry, , Jul-18, Volume: 40, Issue:15, 1997
Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.Journal of medicinal chemistry, , Dec-06, Volume: 39, Issue:25, 1996
Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore.Journal of medicinal chemistry, , Jan-06, Volume: 38, Issue:1, 1995
Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists.Journal of medicinal chemistry, , Oct-16, Volume: 35, Issue:21, 1992
Sortase A-mediated cyclization of novel polycyclic RGD peptides for αBioorganic & medicinal chemistry letters, , 10-01, Volume: 73, 2022
Tuning the Biological Activity of RGD Peptides with Halotryptophans†.Journal of medicinal chemistry, , 01-14, Volume: 64, Issue:1, 2021
[no title available]Journal of medicinal chemistry, , 05-27, Volume: 64, Issue:10, 2021
Novel cilengitide-based cyclic RGD peptides as αvβBioorganic & medicinal chemistry letters, , 04-15, Volume: 30, Issue:8, 2020
Design and synthesis of novel dual-cyclic RGD peptides for αBioorganic & medicinal chemistry letters, , 04-01, Volume: 29, Issue:7, 2019
Cyclization of RGD Peptides by Suzuki-Miyaura Cross-Coupling.Journal of medicinal chemistry, , 08-22, Volume: 62, Issue:16, 2019
Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to αJournal of medicinal chemistry, , 09-13, Volume: 61, Issue:17, 2018
Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme.Journal of medicinal chemistry, , 06-14, Volume: 61, Issue:11, 2018
New potent and selective αvβBioorganic & medicinal chemistry letters, , 05-01, Volume: 27, Issue:9, 2017
Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dual αVβ3 and α5β1 integrin ligands.Bioorganic & medicinal chemistry, , Feb-15, Volume: 24, Issue:4, 2016
Insight to the binding mode of triazole RGD-peptidomimetics to integrin-rich cancer cells by NMR and molecular modeling.Bioorganic & medicinal chemistry, , Mar-01, Volume: 24, Issue:5, 2016
Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity.Journal of medicinal chemistry, , Apr-24, Volume: 57, Issue:8, 2014
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.Journal of medicinal chemistry, , Aug-14, Volume: 57, Issue:15, 2014
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.Journal of medicinal chemistry, , Jul-10, Volume: 57, Issue:13, 2014
Synthesis and in vitro evaluation of a novel radioligand for αvβ3 integrin receptor imaging: [18F]FPPA-c(RGDfK).Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 23, Issue:22, 2013
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes α5β1 and αvβ6: conformational control through flanking amino acids.Journal of medicinal chemistry, , Feb-28, Volume: 56, Issue:4, 2013
Emerging targets in osteoporosis disease modification.Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010
Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity.Bioorganic & medicinal chemistry, , Feb-15, Volume: 17, Issue:4, 2009
Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.Bioorganic & medicinal chemistry, , Apr-15, Volume: 16, Issue:8, 2008
Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008
Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.European journal of medicinal chemistry, , Volume: 42, Issue:3, 2007
Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.Journal of medicinal chemistry, , Mar-09, Volume: 49, Issue:5, 2006
Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.Journal of medicinal chemistry, , Dec-01, Volume: 48, Issue:24, 2005
Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.Journal of medicinal chemistry, , Feb-28, Volume: 45, Issue:5, 2002
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.Journal of medicinal chemistry, , Sep-21, Volume: 43, Issue:19, 2000
Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.Journal of medicinal chemistry, , Apr-08, Volume: 42, Issue:7, 1999
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.Journal of medicinal chemistry, , Sep-21, Volume: 43, Issue:19, 2000
Isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate.Bioorganic & medicinal chemistry letters, , Jan-18, Volume: 9, Issue:2, 1999
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.Journal of medicinal chemistry, , Sep-21, Volume: 43, Issue:19, 2000
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors.Bioorganic & medicinal chemistry letters, , Sep-04, Volume: 10, Issue:17, 2000
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors.Bioorganic & medicinal chemistry letters, , Sep-04, Volume: 10, Issue:17, 2000
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.Journal of medicinal chemistry, , Sep-21, Volume: 43, Issue:19, 2000
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.Journal of medicinal chemistry, , Jun-06, Volume: 40, Issue:12, 1997
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.Journal of medicinal chemistry, , Aug-18, Volume: 38, Issue:17, 1995
Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.Journal of medicinal chemistry, , Apr-08, Volume: 47, Issue:8, 2004
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.Journal of medicinal chemistry, , Sep-21, Volume: 43, Issue:19, 2000
Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.Bioorganic & medicinal chemistry letters, , Oct-18, Volume: 14, Issue:20, 2004
1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists.Bioorganic & medicinal chemistry letters, , Oct-08, Volume: 11, Issue:19, 2001
Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.Journal of medicinal chemistry, , 06-11, Volume: 63, Issue:11, 2020
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.Journal of medicinal chemistry, , Sep-21, Volume: 43, Issue:19, 2000
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.Journal of medicinal chemistry, , Sep-21, Volume: 43, Issue:19, 2000
Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.Journal of medicinal chemistry, , Aug-02, Volume: 39, Issue:16, 1996
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.Journal of medicinal chemistry, , Jul-10, Volume: 57, Issue:13, 2014
Cyclic RGD peptide analogues as antiplatelet antithrombotics.Journal of medicinal chemistry, , May-29, Volume: 35, Issue:11, 1992
Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor.Journal of medicinal chemistry, , Dec-25, Volume: 35, Issue:26, 1992
Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design.Journal of medicinal chemistry, , Oct-09, Volume: 46, Issue:21, 2003
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.Journal of medicinal chemistry, , Jan-13, Volume: 43, Issue:1, 2000
Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.Bioorganic & medicinal chemistry letters, , Jul-05, Volume: 9, Issue:13, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.Bioorganic & medicinal chemistry letters, , Jul-05, Volume: 9, Issue:13, 1999
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.Bioorganic & medicinal chemistry letters, , Nov-17, Volume: 8, Issue:22, 1998
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.Bioorganic & medicinal chemistry letters, , Nov-17, Volume: 8, Issue:22, 1998
Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.Journal of medicinal chemistry, , Jul-18, Volume: 40, Issue:15, 1997
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.Journal of medicinal chemistry, , Sep-21, Volume: 43, Issue:19, 2000
Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.Journal of medicinal chemistry, , Feb-12, Volume: 41, Issue:4, 1998
Cyclization of RGD Peptides by Suzuki-Miyaura Cross-Coupling.Journal of medicinal chemistry, , 08-22, Volume: 62, Issue:16, 2019
Synthesis of a Chloroalkene Dipeptide Isostere-Containing Peptidomimetic and Its Biological Application.ACS medicinal chemistry letters, , Jan-11, Volume: 9, Issue:1, 2018
Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting the αJournal of medicinal chemistry, , 01-12, Volume: 60, Issue:1, 2017
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.Journal of medicinal chemistry, , 11-10, Volume: 59, Issue:21, 2016
Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3.Journal of medicinal chemistry, , Dec-13, Volume: 55, Issue:23, 2012
Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 21, Issue:7, 2011
Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.Journal of medicinal chemistry, , Jan-14, Volume: 53, Issue:1, 2010
Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.Bioorganic & medicinal chemistry, , Apr-15, Volume: 16, Issue:8, 2008
Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 16, Issue:22, 2006
Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.Journal of medicinal chemistry, , Jun-01, Volume: 49, Issue:11, 2006
Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.Journal of medicinal chemistry, , Mar-09, Volume: 49, Issue:5, 2006
Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.Journal of medicinal chemistry, , Dec-01, Volume: 48, Issue:24, 2005
Determination of the binding specificity of an integral membrane protein by saturation transfer difference NMR: RGD peptide ligands binding to integrin alphaIIbbeta3.Journal of medicinal chemistry, , Sep-13, Volume: 44, Issue:19, 2001
Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the alpha V beta 3 receptor.Journal of medicinal chemistry, , Oct-25, Volume: 39, Issue:22, 1996
Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.Journal of medicinal chemistry, , 06-11, Volume: 63, Issue:11, 2020
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 22, Issue:12, 2012
Emerging targets in osteoporosis disease modification.Journal of medicinal chemistry, , Jun-10, Volume: 53, Issue:11, 2010
Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative.Bioorganic & medicinal chemistry letters, , Sep-06, Volume: 14, Issue:17, 2004
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.Journal of medicinal chemistry, , Oct-23, Volume: 46, Issue:22, 2003
Molecular model of the alpha(IIb)beta(3) integrin.Journal of medicinal chemistry, , Dec-04, Volume: 46, Issue:25, 2003
Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin.Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.Journal of medicinal chemistry, , Jan-13, Volume: 43, Issue:1, 2000
Enables
This protein enables 15 target(s):
| Target | Category | Definition |
|---|
| virus receptor activity | molecular function | Combining with a virus component and mediating entry of the virus into the cell. [GOC:bf, GOC:dph, PMID:7621403, UniProtKB-KW:KW-1183] |
| fibronectin binding | molecular function | Binding to a fibronectin, a group of related adhesive glycoproteins of high molecular weight found on the surface of animal cells, connective tissue matrices, and in extracellular fluids. [GOC:hjd] |
| protease binding | molecular function | Binding to a protease or a peptidase. [GOC:hjd] |
| protein disulfide isomerase activity | molecular function | Catalysis of the rearrangement of both intrachain and interchain disulfide bonds in proteins. [EC:5.3.4.1, GOC:vw, Wikipedia:Protein_disulfide-isomerase#Function] |
| protein kinase C binding | molecular function | Binding to protein kinase C. [GOC:jl] |
| platelet-derived growth factor receptor binding | molecular function | Binding to a platelet-derived growth factor receptor. [GOC:ai] |
| integrin binding | molecular function | Binding to an integrin. [GOC:ceb] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| coreceptor activity | molecular function | Combining with an extracellular or intracellular messenger, and in cooperation with a nearby primary receptor, initiating a change in cell activity. [GOC:go_curators] |
| enzyme binding | molecular function | Binding to an enzyme, a protein with catalytic activity. [GOC:jl] |
| identical protein binding | molecular function | Binding to an identical protein or proteins. [GOC:jl] |
| vascular endothelial growth factor receptor 2 binding | molecular function | Binding to a vascular endothelial growth factor receptor 2. [GOC:st] |
| metal ion binding | molecular function | Binding to a metal ion. [GOC:ai] |
| cell adhesion molecule binding | molecular function | Binding to a cell adhesion molecule. [GOC:ai] |
| extracellular matrix binding | molecular function | Binding to a component of the extracellular matrix. [GOC:ai] |
Located In
This protein is located in 18 target(s):
| Target | Category | Definition |
|---|
| nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
| nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| cell-cell junction | cellular component | A cell junction that forms a connection between two or more cells of an organism; excludes direct cytoplasmic intercellular bridges, such as ring canals in insects. [GOC:aruk, GOC:bc, GOC:dgh, GOC:hb, GOC:mah, PMID:21422226, PMID:28096264] |
| focal adhesion | cellular component | A cell-substrate junction that anchors the cell to the extracellular matrix and that forms a point of termination of actin filaments. In insects focal adhesion has also been referred to as hemi-adherens junction (HAJ). [GOC:aruk, GOC:bc, ISBN:0124325653, ISBN:0815316208, PMID:10419689, PMID:12191915, PMID:15246682, PMID:1643657, PMID:16805308, PMID:19197329, PMID:23033047, PMID:26923917, PMID:28796323, PMID:8314002] |
| external side of plasma membrane | cellular component | The leaflet of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface. [GOC:dos, GOC:tb] |
| cell surface | cellular component | The external part of the cell wall and/or plasma membrane. [GOC:jl, GOC:mtg_sensu, GOC:sm] |
| apical plasma membrane | cellular component | The region of the plasma membrane located at the apical end of the cell. [GOC:curators] |
| platelet alpha granule membrane | cellular component | The lipid bilayer surrounding the platelet alpha granule. [GOC:mah, PMID:8467233] |
| lamellipodium membrane | cellular component | The portion of the plasma membrane surrounding a lamellipodium. [GOC:mah] |
| filopodium membrane | cellular component | The portion of the plasma membrane surrounding a filopodium. [GOC:mah] |
| microvillus membrane | cellular component | The portion of the plasma membrane surrounding a microvillus. [GOC:mah] |
| ruffle membrane | cellular component | The portion of the plasma membrane surrounding a ruffle. [GOC:mah] |
| melanosome | cellular component | A tissue-specific, membrane-bounded cytoplasmic organelle within which melanin pigments are synthesized and stored. Melanosomes are synthesized in melanocyte cells. [GOC:jl, PMID:11584301] |
| synapse | cellular component | The junction between an axon of one neuron and a dendrite of another neuron, a muscle fiber or a glial cell. As the axon approaches the synapse it enlarges into a specialized structure, the presynaptic terminal bouton, which contains mitochondria and synaptic vesicles. At the tip of the terminal bouton is the presynaptic membrane; facing it, and separated from it by a minute cleft (the synaptic cleft) is a specialized area of membrane on the receiving cell, known as the postsynaptic membrane. In response to the arrival of nerve impulses, the presynaptic terminal bouton secretes molecules of neurotransmitters into the synaptic cleft. These diffuse across the cleft and transmit the signal to the postsynaptic membrane. [GOC:aruk, ISBN:0198506732, PMID:24619342, PMID:29383328, PMID:31998110] |
| postsynaptic membrane | cellular component | A specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft). Neurotransmitters cross the synaptic cleft and transmit the signal to the postsynaptic membrane. [ISBN:0198506732] |
| extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
| glycinergic synapse | cellular component | A synapse that uses glycine as a neurotransmitter. [GOC:dos] |
Active In
This protein is active in 4 target(s):
| Target | Category | Definition |
|---|
| glutamatergic synapse | cellular component | A synapse that uses glutamate as a neurotransmitter. [GOC:dos] |
| focal adhesion | cellular component | A cell-substrate junction that anchors the cell to the extracellular matrix and that forms a point of termination of actin filaments. In insects focal adhesion has also been referred to as hemi-adherens junction (HAJ). [GOC:aruk, GOC:bc, ISBN:0124325653, ISBN:0815316208, PMID:10419689, PMID:12191915, PMID:15246682, PMID:1643657, PMID:16805308, PMID:19197329, PMID:23033047, PMID:26923917, PMID:28796323, PMID:8314002] |
| cell surface | cellular component | The external part of the cell wall and/or plasma membrane. [GOC:jl, GOC:mtg_sensu, GOC:sm] |
| synapse | cellular component | The junction between an axon of one neuron and a dendrite of another neuron, a muscle fiber or a glial cell. As the axon approaches the synapse it enlarges into a specialized structure, the presynaptic terminal bouton, which contains mitochondria and synaptic vesicles. At the tip of the terminal bouton is the presynaptic membrane; facing it, and separated from it by a minute cleft (the synaptic cleft) is a specialized area of membrane on the receiving cell, known as the postsynaptic membrane. In response to the arrival of nerve impulses, the presynaptic terminal bouton secretes molecules of neurotransmitters into the synaptic cleft. These diffuse across the cleft and transmit the signal to the postsynaptic membrane. [GOC:aruk, ISBN:0198506732, PMID:24619342, PMID:29383328, PMID:31998110] |
Part Of
This protein is part of 10 target(s):
| Target | Category | Definition |
|---|
| integrin alphav-beta3 complex | cellular component | An integrin complex that comprises one alphav subunit and one beta3 subunit. [PMID:12297042] |
| integrin alphaIIb-beta3 complex | cellular component | An integrin complex that comprises one alphaIIb subunit and one beta3 subunit. [PMID:12297042] |
| integrin complex | cellular component | A protein complex that is composed of one alpha subunit and one beta subunit, both of which are members of the integrin superfamily of cell adhesion receptors; the complex spans the plasma membrane and binds to extracellular matrix ligands, cell-surface ligands, and soluble ligands. [PMID:17543136] |
| protein-containing complex | cellular component | A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together. [GOC:dos, GOC:mah] |
| alphav-beta3 integrin-PKCalpha complex | cellular component | A protein complex that consists of an alphav-beta3 integrin complex bound to protein kinase C alpha. [GOC:BHF, GOC:ebc, PMID:16014375] |
| alphav-beta3 integrin-IGF-1-IGF1R complex | cellular component | A protein complex that consists of an alphav-beta3 integrin complex bound to insulin-like growth factor-1 (IGF-1) and type I insulin-like growth factor receptor (IGF1R). IGF1R is a heterotetramer that consists of two alpha-subunits and two beta-subunits. [GOC:BHF, GOC:ebc, PMID:19578119] |
| alphav-beta3 integrin-HMGB1 complex | cellular component | A protein complex that consists of an alphav-beta3 integrin complex bound to high mobility group box 1 protein. [GOC:BHF, GOC:ebc, PMID:20826760] |
| receptor complex | cellular component | Any protein complex that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. [GOC:go_curators] |
| alphav-beta3 integrin-vitronectin complex | cellular component | A protein complex that consists of an alphav-beta3 integrin complex bound to vitronectin. [PMID:10835423] |
| alpha9-beta1 integrin-ADAM8 complex | cellular component | A protein complex that consists of an alpha9-beta1 integrin complex bound to the transmembrane metallopeptidase ADAM8. [PMID:16995821] |
Involved In
This protein is involved in 66 target(s):
| Target | Category | Definition |
|---|
| positive regulation of protein phosphorylation | biological process | Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein. [GOC:hjd] |
| positive regulation of endothelial cell proliferation | biological process | Any process that activates or increases the rate or extent of endothelial cell proliferation. [GOC:add] |
| positive regulation of cell-matrix adhesion | biological process | Any process that activates or increases the rate or extent of cell adhesion to an extracellular matrix. [GOC:hjd] |
| cell-substrate junction assembly | biological process | The aggregation, arrangement and bonding together of a set of components to form a junction between a cell and its substrate. [GOC:mah] |
| cell adhesion | biological process | The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules. [GOC:hb, GOC:pf] |
| cell-matrix adhesion | biological process | The binding of a cell to the extracellular matrix via adhesion molecules. [GOC:hb] |
| integrin-mediated signaling pathway | biological process | The series of molecular signals initiated by an extracellular ligand binding to an integrin on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:mah, GOC:signaling] |
| embryo implantation | biological process | Attachment of the blastocyst to the uterine lining. [GOC:isa_complete, http://www.medterms.com] |
| blood coagulation | biological process | The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers. [PMID:30700128] |
| positive regulation of endothelial cell migration | biological process | Any process that increases the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium. [GOC:BHF, GOC:dph, GOC:tb] |
| positive regulation of gene expression | biological process | Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). [GOC:txnOH-2018] |
| negative regulation of macrophage derived foam cell differentiation | biological process | Any process that decreases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions. [GOC:add, GOC:BHF, GOC:dph, GOC:tb] |
| positive regulation of fibroblast migration | biological process | Any process that increases the rate, frequency or extent of fibroblast cell migration. Fibroblast cell migration is accomplished by extension and retraction of a pseudopodium. [GOC:BHF, GOC:dph, GOC:tb] |
| negative regulation of lipid storage | biological process | Any process that decreases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development. [GOC:BHF, GOC:dph, GOC:tb] |
| response to activity | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an activity stimulus. [GOC:mtg_muscle] |
| smooth muscle cell migration | biological process | The orderly movement of a smooth muscle cell from one site to another, often during the development of a multicellular organism. [CL:0000192, GOC:mtg_muscle] |
| positive regulation of smooth muscle cell migration | biological process | Any process that activates, maintains or increases the frequency, rate or extent of smooth muscle cell migration. [CL:0000192, GOC:mtg_muscle] |
| platelet activation | biological process | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug. [http://www.graylab.ac.uk/omd/] |
| positive regulation of vascular endothelial growth factor receptor signaling pathway | biological process | Any process that activates or increases the frequency, rate or extent of vascular endothelial growth factor receptor signaling pathway activity. [GOC:dgh] |
| cell-substrate adhesion | biological process | The attachment of a cell to the underlying substrate via adhesion molecules. [GOC:mah, GOC:pf] |
| activation of protein kinase activity | biological process | Any process that initiates the activity of an inactive protein kinase. [GOC:mah] |
| negative regulation of lipid transport | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. [GOC:mah] |
| regulation of protein localization | biological process | Any process that modulates the frequency, rate or extent of any process in which a protein is transported to, or maintained in, a specific location. [GOC:dph, GOC:mah, GOC:tb] |
| regulation of actin cytoskeleton organization | biological process | Any process that modulates the frequency, rate or extent of the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins. [GOC:mah] |
| cell adhesion mediated by integrin | biological process | The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via an integrin, a heterodimeric adhesion receptor formed by the non-covalent association of particular alpha and beta subunits. [GOC:add, PMID:12213832, PMID:14754902] |
| positive regulation of cell adhesion mediated by integrin | biological process | Any process that activates or increases the frequency, rate, or extent of cell adhesion mediated by integrin. [GOC:add] |
| positive regulation of osteoblast proliferation | biological process | Any process that activates or increases the rate or extent of osteoblast proliferation. [GOC:mah] |
| heterotypic cell-cell adhesion | biological process | The attachment of a cell to a cell of a different type via adhesion molecules. [GOC:add] |
| substrate adhesion-dependent cell spreading | biological process | The morphogenetic process that results in flattening of a cell as a consequence of its adhesion to a substrate. [GOC:mah, GOC:pf, PMID:17050732] |
| tube development | biological process | The process whose specific outcome is the progression of a tube over time, from its initial formation to a mature structure. Epithelial and endothelial tubes transport gases, liquids and cells from one site to another and form the basic structure of many organs and tissues including lung and trachea, kidney, the mammary gland, the vascular system and the gastrointestinal and urinary-genital tracts. [PMID:12526790] |
| wound healing, spreading of epidermal cells | biological process | The migration of an epidermal cell along or through a wound gap that contributes to the reestablishment of a continuous epidermis. [GOC:bf, PMID:15269788] |
| cellular response to platelet-derived growth factor stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a platelet-derived growth factor stimulus. [GOC:yaf] |
| apolipoprotein A-I-mediated signaling pathway | biological process | The series of molecular signals initiated by apolipoprotein A-I binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:bf, GOC:signaling, PMID:16443932] |
| wound healing | biological process | The series of events that restore integrity to a damaged tissue, following an injury. [GOC:bf, PMID:15269788] |
| apoptotic cell clearance | biological process | The recognition and removal of an apoptotic cell by a neighboring cell or by a phagocyte. [GOC:rk, PMID:14685684] |
| regulation of bone resorption | biological process | Any process that modulates the frequency, rate or extent of bone tissue loss (resorption). [GOC:ai] |
| positive regulation of angiogenesis | biological process | Any process that activates or increases angiogenesis. [GOC:go_curators] |
| positive regulation of bone resorption | biological process | Any process that activates or increases the frequency, rate or extent of bone resorption. [GOC:go_curators] |
| symbiont entry into host cell | biological process | The process by which a symbiont breaches the plasma membrane or cell envelope and enters the host cell. The process ends when the symbiont or its genome is released into the host cell. [GOC:jl] |
| platelet-derived growth factor receptor signaling pathway | biological process | The series of molecular signals initiated by a ligand binding to a platelet-derived growth factor receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:ceb] |
| positive regulation of fibroblast proliferation | biological process | Any process that activates or increases the frequency, rate or extent of multiplication or reproduction of fibroblast cells. [GOC:jid] |
| mesodermal cell differentiation | biological process | The process in which a relatively unspecialized cell acquires the specialized features of a mesoderm cell. [GOC:dgh] |
| positive regulation of smooth muscle cell proliferation | biological process | Any process that activates or increases the rate or extent of smooth muscle cell proliferation. [CL:0000192, GOC:ebc] |
| positive regulation of peptidyl-tyrosine phosphorylation | biological process | Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine. [GOC:ai] |
| negative regulation of lipoprotein metabolic process | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving lipoproteins, any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids. [GOC:ai] |
| negative chemotaxis | biological process | The directed movement of a motile cell or organism towards a lower concentration of a chemical. [GOC:ai, GOC:bf, GOC:isa_complete] |
| regulation of release of sequestered calcium ion into cytosol | biological process | Any process that modulates the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria. [GOC:ai, GOC:tb] |
| regulation of serotonin uptake | biological process | Any process that modulates the frequency, rate or extent of the directed movement of the monoamine neurotransmitter serotonin into a cell. [GOC:ai] |
| angiogenesis involved in wound healing | biological process | Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels and contribute to the series of events that restore integrity to a damaged tissue, following an injury. [GOC:dph, PMID:15039218] |
| positive regulation of ERK1 and ERK2 cascade | biological process | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. [GOC:mah] |
| platelet aggregation | biological process | The adhesion of one platelet to one or more other platelets via adhesion molecules. [GOC:BHF, GOC:vk] |
| cellular response to mechanical stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mechanical stimulus. [GOC:mah] |
| cellular response to xenobiotic stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:krc, GOC:mah] |
| positive regulation of glomerular mesangial cell proliferation | biological process | Any process that increases the frequency, rate or extent of glomerular mesangial cell proliferation. [GOC:mtg_kidney_jan10] |
| blood coagulation, fibrin clot formation | biological process | A protein activation cascade that contributes to blood coagulation and consists of the cascade of enzymatic reactions initiated by physical damage to the wall of a blood vessel, leading to the formation of a formation of a fibrin clot at the site of the injury. The process also includes numerous positive and negative regulatory events. [GOC:add, GOC:mah, GOC:pde] |
| maintenance of postsynaptic specialization structure | biological process | A process which maintains the organization and the arrangement of proteins in the presynaptic specialization. [GOC:dos] |
| regulation of postsynaptic neurotransmitter receptor internalization | biological process | Any process that modulates the frequency, rate or extent of endocytosis of neurotransmitter receptor at the postsynapse. [GOC:ai] |
| regulation of postsynaptic neurotransmitter receptor diffusion trapping | biological process | Any process that modulates the frequency, rate or extent of postsynaptic neurotransmitter receptor diffusion trapping. [GOC:aruk, GOC:bc, PMID:20935643] |
| positive regulation of substrate adhesion-dependent cell spreading | biological process | Any process that activates or increases the frequency, rate or extent of substrate adhesion-dependent cell spreading. [GOC:TermGenie, GOC:yaf] |
| positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway | biological process | Any process that activates or increases the frequency, rate or extent of adenylate cyclase-inhibiting opioid receptor signaling pathway. [GOC:sjw, GOC:TermGenie, PMID:17157995] |
| regulation of trophoblast cell migration | biological process | Any process that modulates the frequency, rate or extent of trophoblast cell migration. [GOC:BHF, GOC:TermGenie] |
| regulation of extracellular matrix organization | biological process | Any process that modulates the frequency, rate or extent of extracellular matrix organization. [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:22357537] |
| cellular response to insulin-like growth factor stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin-like growth factor stimulus. [PMID:20042609] |
| negative regulation of endothelial cell apoptotic process | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell apoptotic process. [GOC:BHF, GOC:mah, GOC:mtg_apoptosis] |
| positive regulation of T cell migration | biological process | Any process that activates or increases the frequency, rate or extent of T cell migration. [GOC:mah] |
| cell migration | biological process | The controlled self-propelled movement of a cell from one site to a destination guided by molecular cues. [GOC:cjm, GOC:dph, GOC:ems, GOC:pf, Wikipedia:Cell_migration] |